Opioid prescribing in adults with and without psoriasis - 09/11/20
Doi : 10.1016/j.jaad.2020.03.080
Megan H. Noe, MD, MPH, MSCE a, ⁎ 
, Daniel B. Shin, PhD b, Mackenzie R. Wehner, MD, MPhil b, c, d, David J. Margolis, MD, PhD b, e, Joel M. Gelfand, MD, MSCE b, e
, Daniel B. Shin, PhD b, Mackenzie R. Wehner, MD, MPhil b, c, d, David J. Margolis, MD, PhD b, e, Joel M. Gelfand, MD, MSCE b, e a Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, University of Pennsylvania, Philadelphia
c Department of Health Services Research, The University of Texas M.D. Anderson Cancer Center, Houston
d Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston
e Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia
∗Correspondence to: Megan Noe, MD, MPH, MSCE, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115
| Funding sources: Supported in part by a Center Core Center of Excellence Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR069589). Dr Noe is supported by a Career Development Award (K23-AR073932) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr Wehner was supported by a National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health Dermatology Research Training grant (T32 AR7465; principal investigator: Sarah E. Millar). |
|
| Disclosure: Dr Margolis receives research funding as the principal investigator via the Trustees of the University of Pennsylvania (R01-AR060962, R01- AR070873, and R01-DK116199) and from the National Institutes of Health and Valeant Pharmaceuticals (PEER study) and Sunovion Pharmaceuticals (none of this funding was used for this study), and he has consulting activities primarily as a member of data monitoring boards or scientific advisory boards with Leo, Johnson and Johnson, Pfizer, Sanofi, Kerecis, and Cell Constructs (none of these activities are associated with the outcomes of this study). Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologic, and Novartis. Drs Noe, Shin, and Wehner have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 6
P. 1777-1779 - décembre 2020 Retour au numéro
Article précédent
- Ambient ultraviolet radiation and major salivary gland cancer in the United States
- Zhi-Ming Mai, Michael R. Sargen, Rochelle E. Curtis, Ruth M. Pfeiffer, Margaret A. Tucker, Elizabeth K. Cahoon
- The adverse effect profile of acitretin in a pediatric dermatology population—Longitudinal cohort study and recommendations for monitoring
- Anna Cave, Isabella Plumptre, Jemima E. Mellerio, Anna E. Martinez, Veronica A. Kinsler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?